Navigation Links
Amicus Therapeutics Announces Third Quarter 2008 Financial Results
Date:11/3/2008

apies, Inc. ("Shire"), is engaged in ongoing discussions with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) and will provide an update by the end of the year. A final decision on the global development strategy will follow the conclusion of the discussions with both agencies. Subject to the outcome of the discussions, the Company expects to initiate Phase 3 development of Amigal in the first half of 2009.

In addition, 23 of the original 26 patients continue to be treated in a voluntary Phase 2 extension study designed to monitor long-term safety and efficacy and to evaluate additional doses and dose regimens. Data from this extension study are expected in Q1 2009 prior to the start of the Phase 3 study.

Gaucher Disease:

Plicera(TM) (isofagomine tartrate) is an investigational, oral therapeutic in Phase 2 development for the treatment of Gaucher disease. As previously disclosed, a 6-month Phase 2 clinical trial of Plicera in patients naive to ERT is ongoing and Amicus expects the results of this study to be available in 2009.

Pompe Disease:

AT2220 (1-deoxynojirimycin HCl) is an investigational, oral therapeutic being developed for the treatment of Pompe disease. As previously disclosed, a Phase 2 clinical trial of AT2220 in adult Pompe patients is ongoing and includes an 11 week treatment period with an optional extension study.

In addition, Amicus is conducting preclinical animal studies to evaluate the effects of administering AT2220 in combination with enzyme replacement therapy. Based on the results of the preclinical work, Amicus will consider initiating a clinical trial of the AT2220-ERT combination treatment in Pompe patients.

Other Chaperone Programs:

Amicus continues to invest in research and development to assess the potential for using pharmacological chaperones to treat a broader range of human genetic diseases beyond lysosomal storage diseases. As part of this
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
2. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
3. Amicus Therapeutics Opens Research Facility in San Diego
4. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
5. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
6. Amicus Therapeutics Announces First Quarter 2008 Financial Results
7. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
11. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... lessons often have it that American Indians largely were ... pox, influenza and tuberculosis brought to the New World ... about 20 million people lived in the Americas shortly ... were killed by European diseases., But new research led ... and Johannes Krause of the University of Tubingen in ...
(Date:8/20/2014)... High performance computing (HPC) will be ... climate and Earth system model to address the ... Eight national laboratories, including Lawrence Livermore , ... Atmospheric Research, four academic institutions and one private-sector ... laboratories include Argonne, Brookhaven, Lawrence Berkeley, Los Alamos, ...
(Date:8/20/2014)... The 6th Annual Arrowhead Personalized and ... 29-30 in San Francisco, CA. This year’s conference brings ... and clinicians focused on addressing and solving the significant ... twelve years since the sequencing of the human genome, ... pharmacogenetic information in the label and molecular diagnostics have ...
(Date:8/20/2014)... nerves in your ear could improve the health of ... the University of Leeds used a standard TENS machine ... electrical pulses to the tragus, the small raised flap ... of the ear canal. , The stimulation changed the ... reducing the nervous signals that can drive failing hearts ...
Breaking Biology Technology:Unusual discovery leads to fascinating tuberculosis theory 2Unusual discovery leads to fascinating tuberculosis theory 3New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 36th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2'Tickling' your ear could be good for your heart 2
... RATON, Fla., Feb. 17, 2011 Sensus ... participation in the 9th Annual South Beach ... 17-21, 2011.  The South Beach Symposium™ is a comprehensive ... and practice management. Sensus Healthcare is featuring superficial radiotherapy ...
... of Santiago de Compostela (USC) have analysed levels of radon, ... The results show that 34% of these schools exceed the ... inhalation of radon is associated with lung cancer. "Out ... had radon levels in excess of 400 Bequerels/m3 in some ...
... a significant component of the defense system of many ... armies and terrorist organizations, and constitute a threat to ... solutions against them have limited efficiency. A multidisciplinary ... succeeded in developing an enzyme that breaks down such ...
Cached Biology Technology:Sensus Healthcare Announces Its Exhibitor Attendance at the 9th Annual South Beach Symposium™ 234 percent of Galician secondary schools exceed maximum recommended radon levels 2Weizmann Institute scientists used accelerated evolution to develop enzymes that provide protection against nerve gas 2Weizmann Institute scientists used accelerated evolution to develop enzymes that provide protection against nerve gas 3Weizmann Institute scientists used accelerated evolution to develop enzymes that provide protection against nerve gas 4
(Date:8/21/2014)... implications for life in other extreme environments, both on ... Associate Professor of Biological Sciences Brent Christner and fellow ... this week published a paper confirming that the waters ... (2600 feet) beneath the surface of the West Antarctic ... than 400 subglacial lakes and numerous rivers and streams ...
(Date:8/21/2014)... to Wednesday, Oct. 18-22, 2014 , WHERE: ... Drive, San Diego, CA 92101 , WHAT: ... presentations of the latest research in human genetics. ... featuring high-scoring abstracts on rare genetic variants in ... and treatment for sun sensitivity (Saturday, Oct. 18, ...
(Date:8/21/2014)... researchers at Louisiana Tech University has developed ... 3D printers and materials to fabricate custom ... chemotherapeutic compounds for targeted drug delivery. , ... research faculty from Louisiana Tech,s biomedical engineering ... filament extruders that can make medical-quality 3D ...
Breaking Biology News(10 mins):800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 2800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 3800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 4American Society of Human Genetics 2014 Annual Meeting 2Louisiana Tech University researchers use 3D printers to create custom medical implants 2Louisiana Tech University researchers use 3D printers to create custom medical implants 3
... Washington, D.C. -- Disease statistics buried within patient ... and organized to depict geographic patterns, allowing the discovery ... Penn State geographer. "The use of interactive maps ... to greater insight into complex events like the spread ...
... region has a hot, wet climate and a lot of ... a really good chance the region will also contain numerous ... study examining the geography of human disease, led by Dr. ... team of biologists and social scientists, shows that that one ...
... world-wide project "MAGICPAH", coordinated by the Braunschweiger Helmholtz-Zentrums ... Braunschweig- HZI), is examining how bacterial communities are ... aromatic hydrocarbons. "MAGICPAH" is a collaboration of thirteen ... enterprises have initiated the project today at the ...
Cached Biology News:Visualization of geographic patterns may predict spread of disease 2Study pins factors behind geography of human disease 2Study pins factors behind geography of human disease 3Improving the degradation of toxic hydrocarbons 2
ANTI FLAG EP CL VEC...
Cross reactivity to St. Louis encephalitis (MSI-7) is determined by ELISA....
EGTA, 10 g. Ethylene glycol-O,O-bis-[2-amino-ethyl]-N,N,N,N,-tetraacetic acid.Assay: > 99.0%. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
RABBIT ANTI HUMAN ATR (aa2122-2380) Immunogen: Human ATR peptide, amino acids 2122-2380...
Biology Products: